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Abstract
Human rhinoviruses (HRV) cause the majority of common colds and acute exacerbations of asthma and chronic obstructive
pulmonary disease (COPD). Effective therapies are urgently needed, but no licensed treatments or vaccines currently exist.
Of the 100 identified serotypes, ,90% bind domain 1 of human intercellular adhesion molecule-1 (ICAM-1) as their cellular
receptor, making this an attractive target for development of therapies; however, ICAM-1 domain 1 is also required for host
defence and regulation of cell trafficking, principally via its major ligand LFA-1. Using a mouse anti-human ICAM-1 antibody
(14C11) that specifically binds domain 1 of human ICAM-1, we show that 14C11 administered topically or systemically pre-
vented entry of two major groups of rhinoviruses, HRV16 and HRV14, and reduced cellular inflammation, pro-inflammatory
cytokine induction and virus load in vivo. 14C11 also reduced cellular inflammation and Th2 cytokine/chemokine production
in a model of major group HRV-induced asthma exacerbation. Interestingly, 14C11 did not prevent cell adhesion via human
ICAM-1/LFA-1 interactions in vitro, suggesting the epitope targeted by 14C11 was specific for viral entry. Thus a human
ICAM-1 domain-1-specific antibody can prevent major group HRV entry and induction of airway inflammation in vivo.
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Introduction
Human rhinoviruses (HRVs) infect the upper respiratory tracts
of healthy subjects and cause around three quarters of common
colds [1,2]. Recently, it has become clear that HRVs are also
major causes of severe, life-threatening illnesses in susceptible
populations: 50–85% of acute asthma exacerbations are now
known to be caused by HRV infections across all age groups
[3,4,5,6]. Further, wheezing illnesses in infancy caused by HRVs
are strongly associated with a very high risk of later development
of childhood asthma [7,8,9]. HRV infections are also associated
with the majority of acute exacerbations of chronic obstructive
pulmonary disease (COPD) [10,11] and cystic fibrosis [12] and
cause life-threatening illnesses in susceptible populations such as
infants [13], the elderly [14] and immuno-compromised individ-
uals [15]. Against this background, there is an urgent need to
develop effective medications to combat HRV induced illnesses.
To date there are no licensed treatments or vaccinations.
Rhinoviruses are positive-stranded RNA viruses of the Picorna-
viridae family and more than 100 antigenically distinct serotypes
have been identified [1,16,17]. Serotyped strains of HRVs are
classified by use of their entry receptor into minor group viruses,
which comprise ,10% of identified serotypes and use low-density-
lipoprotein receptor and related molecules [17] and major group
viruses, comprising ,90% of identified serotypes, which use
intercellular adhesion molecule 1 (ICAM-1, CD54) as their
receptor [2,16]. Thus ICAM-1 is an attractive target for
development of new therapies to combat major group HRV
infections.
However, apart from its role as HRV receptor, ICAM-1 also
has important host functions and in particular it is critical in host
defence against numerous pathogens via its role in leukocyte
recruitment and activation [18,19,20]. Thus inhibiting the
function of ICAM-1 has potential to interfere not only with
HRV cell binding, but also to impair host defence by inhibiting its
interaction with its natural host ligands. ICAM-1 is a member of
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the immunoglobulin (Ig) superfamily and the extracellular portion
of the molecule has five Ig-like domains termed D1 as the most
distal, to D5 as the most proximal to the cell membrane. HRV
serotypes binding ICAM-1 have been reported to bind only to D1,
while LFA-1 and Mac-1 bind to domains D1 and D3, respectively
[21,22,23]. Thus antibodies specific to D1 of ICAM-1 would be
needed to interfere with HRV infection; however they could
potentially interfere with ICAM-1/LFA-1 interactions.
In the present report we characterise an anti-human ICAM-1-
specific antibody (14C11) and show its binding is specific to human
ICAM-1 D1, that it is inhibitory against multiple major group
HRV serotypes in vitro, and prevents major group HRV infection
and HRV induced exacerbation of allergic airway inflammation in
vivo. We also show that this antibody does not inhibit human
ICAM-1/LFA-1 interactions and therefore should not interfere
with cellular trafficking.
Results
14C11 binds in domain 1 of human ICAM-1, does not
bind to mouse ICAM-1 and does not inhibit human
ICAM-1/LFA-1 interaction
ICAM-1 plays an important role in trans-endothelial migration
of leukocytes and activation of T cells via LFA-1. In addition it is
also the entry receptor for major group HRVs. We were interested
in identifying antibodies suitable to inhibit HRV-ICAM-1
interactions for the potential treatment of HRV-induced exacer-
bations in airway disease without compromising the host leukocyte
trafficking by interference of ICAM-1 interactions with the
integrin LFA-1. We thus initially investigated the binding
properties of the commercially available antibodies to human
ICAM-1 - 14C11 and 84H10 - to determine whether they bind to
domain 1 of human ICAM-1 (Hu ICAM-1) the putative binding
site for viral entry [2,16]. Biotinylated Hu ICAM-1, a chimeric
protein consisting of domain 1 of human ICAM-1 and domains 2–
5 of mouse ICAM-1 (Hu1 Mu2-5), murine ICAM-1 (Mu ICAM-1)
and insulin as a control protein were incubated with 14C11 or
84H10 to test their binding specificity. We found binding of
14C11 and 84H10 to both Hu ICAM-1 and Hu1 Mu2-5
confirming that 14C11 binds specifically to domain 1 of human
ICAM-1, but not to murine ICAM-1 (Figure 1A and 1B).
Additionally, cells were stimulated with PMA in a human T cell
(Jurkat cell) adhesion assay, to determine whether 14C11 or
84H10 could inhibit human ICAM-1/LFA-1 interactions. Neither
14C11 nor the isotype control was able to prevent cell adhesion via
LFA-1 whereas the anti-ICAM-1 antibody 84H10 blocked the
ICAM-1/LFA-1 interaction and failed to retain the labelled Jurkat
cells (Figure 1C). These results emphasise that the domain
specificity of 14C11 suggests it will not block human ICAM-1/
LFA-1 interaction. Regarding binding to other members of the
immumoglobulin (Ig) superfamily structurally related to huICAM-
1 the specification provided by the manufacturer stated that
14C11 showed no cross-reactivity with rabbit ICAM-1, human
ICAM-2, human ICAM-3, human VCAM-1, and ‘mouse DCC’.
We also demonstrated the binding specificity of 14C11 observing
binding to human ICAM-1 and a chimeric mouse ICAM-1 with
domain 1 substituted for human ICAM-1 Ig domain 1. In the
same assay no binding to mouse ICAM-1, human ICAM-2,
human ICAM-3, human ICAM-5 or human VCAM-1 was
observed. (Fig. S1).
The anti-ICAM-1 antibody inhibits major group HRV
replication in vitro
Next we tested the effect of 14C11 in an in vitro HRV infection
assay. Using a cytopathic effect assay (CPE) we showed the
antiviral effect of 14C11 in inhibiting the replication of HRV16
(Figure 2A) and HRV14 (Figure 2B) with increasing concentration
of antibody. 14C11 did not inhibit CPE caused by infection with
minor group serotype HRV25 (Figure 2C) consistent with ICAM-
1 blockade-specific mechanism of action. Isotype control antibody
did not prevent replication of HRV16 or HRV14 in HeLa Ohio
cells. Additionally, the median tissue culture inhibitory concen-
tration (IC50) was assessed for a wide range of major group HRVs
as indicated in Figure 2D, suggesting a consistent prevention of
replication by 14C11 for many major type HRVs, the great
majority with sub-nanoMolar IC50s. These results emphasise that
the domain specificity of 14C11 indicates it inhibits human
ICAM-1-HRV binding but does not block human ICAM-1/LFA-
1 interaction.
The anti-ICAM-1 antibody 14C11 inhibits major group
HRV induced inflammation and lung virus RNA levels in
vivo
To test the effect of the anti-ICAM-1 antibody 14C11 in an in
vivo major group HRV infection model, we challenged transgenic
Balb/c mice over-expressing extracellular domain 1 and 2 of
human ICAM-1 (tg+) and non-transgenic littermates (tg2) with
major group HRV16 as described previously [24]. Transgenic
positive (tg+) mice were dosed 2 hours prior to viral challenge with
3 doses of 14C11 intranasally; 1 mg, 10 mg and 100 mg/mouse
14C11 or 100 mg/mouse isotype control and were subsequently
infected intranasally with major group HRV16. Transgenic
negative (tg2) mice were challenged with the same dose of
HRV16 as the tg+ littermates. BAL was performed 2 days after
infection. Tg+ mice showed a robust cell infiltration and cytokine
and chemokine production in the lung compared to tg2 mice for
all parameters measured. Isotype control treatment did not alter
HRV induced airway inflammation for any endpoint (Figure 3).
Antibody treatment in the absence of infection did not cause any
measurable immune response in the lung (data not shown). 14C11
significantly reduced total BAL cell, macrophage, neutrophil and
Author Summary
Viruses exploit receptors on the host cell to cause
infection. Therapies aimed at blocking virus-receptor
interactions have the potential to prevent viral disease.
Cellular receptors are also important for normal host cell
function. Therefore, new therapies targeting these recep-
tors to block viral infection may also inadvertently alter the
physiology of the host cell. Viral pathogens, such as the
cold virus (rhinovirus), are believed to be the major cause
of asthma attacks and exacerbations in chronic obstructive
pulmonary disease (COPD). In this study, we show that it is
possible to identify novel therapeutic antibodies that block
infection with rhinovirus without impairing the receptors’
main function of cell adhesion. We then use animal models
that show that an antibody can inhibit virus-induced lung
inflammation and disease. Moreover, we show that this
antibody can also inhibit a virally induced asthma
exacerbation. This work is relevant in that it shows that
antibodies can be tailored to distinct regions of viral
receptors to block infection without inhibiting the recep-
tors’ normal cellular function. This is important for the
development of new treatments that will prevent diseases
caused by infection with rhinovirus, such as exacerbations
of asthma and COPD.
ICAM-1 Blockade and Rhinovirus Infection
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lymphocyte numbers in a dose dependent manner (Figure 3A).
HRV induction of the pro-inflammatory cytokines IL-1b and IL-
6, the chemokines CXCL1, CXCL11 and CXCL10, as well as
type III interferon IFNl2/3 were all significantly reduced in BAL
by 14C11 treatment (Figure 3B). Induction of IL-1b, IL-6 and
CXCL1 were also significantly reduced in lung homogenate
(Figure 3C). The kinetics of HRV16 viral load was assessed by
real-time PCR. Tg+ mice and tg+ mice pre-treated with isotype
control showed increased HRV16 vRNA levels at 6 to 9 hours
after challenge compared to tg2 mice, while the HRV16 vRNA
levels were completely abolished by 14C11 treatment (Figure 3D).
H&E staining of lung sections from tg+mice infected with HRV or
isotype pre-treated HRV infected mice showed increased inflam-
matory cells in the lung. However, in 14C11 treated animals as
well as control tg2 animals challenged with HRV only marginal
inflammation was observed (Figure 3E). The human ICAM-1
specific antibody 14C11 could therefore prevent HRV16 entry
and replication as well as induction of airway inflammation in vivo.
To investigate further how 14C11 influences airway inflamma-
tion induced by another major group virus, we analysed BAL from
HRV14 infected mice. We chose this serotype as HRV14 is in the
HRV-B type group and is genotypically distinct from HRV16
(which belongs to the HRV genotype group A). BAL cell analysis
revealed increases in total BAL cell, neutrophil and lymphocyte
numbers in HRV14 infected tg+ mice and HRV14 infected tg+
mice pre-treated with isotype control compared to tg2 controls.
Virus induction of total BAL cell, neutrophil and lymphocyte
numbers were significantly reduced in tg+ mice pre-treated with
14C11 (Figure S1A). The induction of proinflammatory cytokine
IL-6, the chemokines CXCL1, CXCL11 and CXCL10 as well as
type III interferon IFNl2/3 were not different in tg+mice infected
with HRV14 and isotype pre-treated tg+ infected mice. However,
induction of cytokines, chemokines and type III interferon IFNl2/
3 in both BAL (Figure S1B) and lung homogenate (Figure S1C)
were reduced by 14C11 treatment in HRV infected tg+ mice, to
levels similar to those in HRV14 challenged tg2 control mice.
Thus 14C11 is able to inhibit group B HRV-as well as group A
HRV-induced inflammation.
Systemic administration of the anti-ICAM-1 antibody
14C11 is protective against HRV16-induced airway
inflammation in vivo
As therapeutic antibodies for the treatment of respiratory
diseases are typically dosed parenterally [25] we next evaluated the
pharmacological activity of 14C11 via the intravenous route of
administration. Mice were pre-treated 24 hours prior to viral
Figure 1. 14C11 binds in domain 1 of human ICAM-1, does not bind to mouse ICAM-1 and does not inhibit human ICAM-1/LFA-1
interaction. (A)14C11 and (B) 84H10 antibody were tested for binding of antigens (human ICAM-1 (Hu ICAM-1), mouse ICAM-1 (Mu ICAM-1) and a
recombinant protein consisting of human ICAM-1 D1 and mouse ICAM-1 D2-5 (Hu1 Mu2-5)). Jurkat E6.1 cells were labelled with Calcein-AM dye.
Serial dilutions of the antibodies 14C11, 84H10 and isotype control were added in an ICAM-1-Fc coated plate. (C) PMA and labelled Jurkat E6.1 cells
were added into the plate. Binding to LFA-1 was determined by fluorescein detection. Data were analysed by normalising values to no PMA (0%
signal) and PMA no antibody (100% signal) controls. Data are a representative of three experiments for (A) and (B) and four to seven experiments for
(C). Data are expressed as mean (6 SEM).
doi:10.1371/journal.ppat.1003520.g001
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challenge and then cell influx and pro-inflammatory cytokine
release were assessed. Control groups of HRV16 infected tg+ and
isotype treated control mice showed elevated levels of total BAL
cells, lymphocytes and neutrophils on day 2 after infection
compared to HRV16 challenged tg2 mice (Figure 4A).). Admin-
istration of intravenous 14C11 24 h prior to HRV infection dose
dependently reduced airways inflammation in terms of total
numbers of BAL cells, lymphocytes and neutrophils. (Figure 4A).
14C11 significantly reduced in a dose-dependent manner the
induction of CXCL1, CXCL11 and CXCL10 in the BAL of tg+
HRV16 infected mice compared to untreated or isotype pre-
treated HRV16 infected tg+ mice (Figure 4B). Induction of IL-1b
and IL-6 as well as IFNl2/3 was also reduced by 14C11 treatment
in tg+ HRV16 infected mice (Figure S2A). Similar results were
found in lung homogenate for protein levels of IL-1b, IL-6 and
CXCL1 (Figure S2B). Systemic administration of 14C11 is
therefore protective against HRV16 infection in terms of induction
of airway inflammation in vivo.
14C11 does not influence inflammation induced via
mechanisms independent of human ICAM-1 in vivo
Antibodies are large complex proteins that not only bind
antigen via the variable domain but also bind Fc receptors on
antigen presenting cells by binding via the constant domain.
Moreover 14C11 is a mouse anti-human IgG1 type antibody and
could potentially bind to mouse Fcc receptors on innate immune
cells, such as FccRIIB, providing a potential inhibitory signal. To
investigate whether the 14C11 antibody non-specifically inhibited
inflammation by cross-linking human ICAM-1 and binding Fcc
receptor cells we therefore investigated whether 14C11 could
inhibit cellular inflammation evoked in tg+ mice, but by a non
human ICAM-1 mediated infection using minor group HRV1B
infection. Transgenic negative and transgenic positive littermates
were dosed intravenously 24 hours prior to viral infection with or
without 20 mg/kg isotype control or 14C11 antibody and
consequently infected with UV-inactivated HRV1B or with
HRV1B. Significant induction of total BAL cells and neutrophils
at day 1 post infection and lymphocyte numbers at day 4 could be
observed compared to mice infected with UV-inactivated HRV1B
in both types of mice (Figure 5A). Induction by HRV1B of each
cell type was virtually identical in tg+ and tg2 mice, suggesting
that the transgenic over-expression of the chimeric human/mouse
ICAM-1 molecule did not influence cell trafficking via potential
interactions with mouse LFA-1.
Pre-treatment with isotype control or 14C11 antibody in
transgene positive mice infected with HRV1B did not alter the
Figure 2. 14C11 inhibits major group HRV replication in vitro. Ohio HeLa cells were pre-incubated with serial dilutions of 14C11 or isotype
control and infected with (A) HRV16, (B) HRV14 and (C) minor group HRV25. The antiviral effect of 14C11 was determined by CPE reduction assay and
expressed as % of control. (D) IC50s for 14C11 were determined for major HRVs by CPE assay as indicated in. Experiment (A), (B) and (C) were
performed in sextuplicates and (D) is a pool of two independent experiments. Data are expressed as mean (6 SEM).
doi:10.1371/journal.ppat.1003520.g002
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induction of cellular inflammation, while infiltration of inflamma-
tory cells in the lung of HRV16 infected transgene positive mice
was significantly reduced by 14C11, showing that 14C11 was able
to block HRV entry and replication in the same experiment
(Figure 5A and S3A). Similarly, 14C11 administration did not
reduce HRV1B-induction of CXCL1, CXCL10 or CXCL11, nor
the cytokines IL-1b, IL-6 or IFNl2/3 in BAL or lung homogenate
(Figure S3B and C).
We also explored whether 14C11 would non-specifically inhibit
inflammatory responses using an LPS challenge model in the
presence or absence of 14C11 antibody. Although we would not
expect 14C11 to interfere with mouse LFA-1 - mouse ICAM-1
interaction it was still necessary to demonstrate the specificity of
14C11 by performing studies in a model of airway inflammation
that did not require human ICAM-1. Mice challenged with LPS,
LPS and systemic administered isotype control or 14C11 showed
significant increases in total BAL cells on day 1 and neutrophil and
lymphocyte numbers on day 4 after infection (Figure 5B), which
were not altered by pre-treatment with 14C11. In addition, pro-
inflammatory cytokines were also unaffected by 14C11 treatment
(Figure S3D and E).
Taken together, this indicates that the human ICAM-1 specific
antibody 14C11 could prevent airway inflammation in vivo for two
major group HRVs, HRV16 and HRV14, but had no non-
specific effects on inflammation induced by a stimuli involving
human ICAM-1 independent mechanisms.
Sustained effect of a single dose of the anti-ICAM-1
antibody 14C11 on inhibition of HRV16 induced airway
inflammation in vivo
We then asked whether the progression of inflammatory
responses to viral infection at later time points is altered by
14C11 to shed light on whether 14C11 simply retards, or
completely arrests HRV16 infection. Therefore, we dosed tg+
mice intranasally 2 hours prior to viral infection either with or
without 100 mg/mouse 14C11 antibody or 100 mg/mouse isotype
control and screened for airway inflammation at day 2, 4 and 7
post infection. Tg2 mice received the same dose of HRV16 as all
other groups (Figure 6). In HRV16 infected tg+ mice as well as in
infected tg+ mice pre-treated with isotype control total BAL cell
numbers peaked at day 2 after infection and stayed increased till
Figure 3. 14C11 antibody inhibits major group HRV16 infection in vivo. Groups of 7 mice were dosed intranasally with 14C11 or isotype
control 2 hours prior to intranasal infection with HRV16. (A) Total BAL cells, macrophages, lymphocytes and neutrophils were assessed with
differentially cytospin counts day 2 after infection. (B) Levels of proinflammatory cytokines and chemokines IL-1b, IL-6, CXCL1, IFNl2/3, CXCL11 and
CXCL10 in cell-free BAL were determined by MSD or quantitative ELISA 2 days after infection. (C) Proinflammatory cytokines and chemokines IL-1b, IL-
6 and CXCL1 in lung homogenate were assessed with MSD 2 days after infection. (D) Groups of 3–5 mice were dosed intranasally with 14C11 or
isotype control 2 hours prior to intranasal infection with HRV16 and vRNA in lung tissue was assessed by qPCR at the timepoints indicated. (E)
Inflammatory cells in the lungs prior to infection (uninfected) and at 12 hours post-infection (12 p.i.) of huICAM negative (tg2) and huICAM-
expressing (tg+) mice without antibody treatment, or for tg+ mice following isotype control antibody (tg+ iso) or 14C11 antibody treatment (tg+
14C11) assessed by H&E staining Arrows indicate peribronchial cellular inflammation. Data are expressed as mean (6 SEM). Significance was assessed
by One-way ANOVA test with Bonferroni’s Multiple Comparison test as post-test. ***p,0.001 and **p,0.01 vs HRV16 infected transgenic negative
mice; #p,0.05, ##p,0.01 and ###p,0.001 vs HRV16 infected transgenic positive mice. Data are representative of 3 independent experiments each.
doi:10.1371/journal.ppat.1003520.g003
Figure 4. Effect of systemically dosed 14C11 antibody on HRV16 infection in vivo. Mice were dosed intravenously with 14C11 24 hours
prior to intranasal infection with HRV16 (n = 9 for tg2 group; n = 6 for tg+ groups). (A) Total BAL cells, amacrophageslymphocytes and neutrophils
were assessed by cytospin 2 days after infection. (B) The chemokines CXCL1, CXCL11 and CXCL10 in BAL were determined by MSD or quantitative
ELISA 2 days after infection. Data are expressed as mean (6 SEM). Significance was assessed by One-way ANOVA test with Bonferroni’s Multiple
Comparison test as post-test. **p,0.01 and ***p,0.001 vs HRV16 infected transgenic negative mice; #p,0.05, ##p,0.01 and ###p,0.001 vs
HRV16 infected transgenic positive mice; Data are representative of 3 independent experiments.
doi:10.1371/journal.ppat.1003520.g004
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day 7. Counts of total BAL cells in tg+ mice pre-treated with
14C11 revealed the same total BAL cell numbers as those
observed in tg2 mice challenged with HRV16 up to day 7.
Macrophages and lymphocytes peaked at day 4 after infection for
the tg+ positive HRV16 group and mice pre-treated with isotype
control; however macrophage numbers showed a prolonged
increase while lymphocyte numbers decreased after day 4 and
returned close to baseline. 14C11 significantly reduced macro-
phage and lymphocyte numbers to levels found in tg2 littermates
challenged with HRV16. Neutrophils were also recruited and
highest levels of neutrophils could be observed at day 2 post-
infection in HRV16 infected tg+ mice or isotype-control pre-
treated and HRV16 infected tg+ mice. A single dose of 14C11
significantly reduced the number of neutrophils to control levels
found in challenged tg2 mice, over a sustained period of 7 days
(Figure 6A).
IL-1b, IL-6 and the chemokines CXCL1, CXCL11 and
CXCL10 as well as IFNl2/3 in the BAL peaked at day 2 after
infection in HRV16 infected tg+ mice and those pre-treated with
isotype control, whereas tg2 littermates and 14C11 treated
HRV16 infected tg+ mice failed to induce cytokine and
chemokine production. All cytokines and chemokines returned
to baseline levels on day 4 of infection, except IFNl2/3 which
could still be detected on day 4 in tg+ infected with HRV16 and
isotype control treated animals, but not in tg2 mice or tg+ mice
pre-treated with 14C11 (Figure 6B and S4A). Similar results were
found in lung homogenate for levels of IL-1b, IL-6 and CXCL1
protein (Figure S4B).
We next checked the influence of 14C11 on the adaptive
immune response by measuring HRV16-specific antibodies.
HRV16 infected tg+ and isotype control pre-treated mice showed
increased levels of HRV16-specific IgG1 and IgG2a in serum on
day 7 post-infection. Levels of HRV16 specific IgG1 and IgG2a
were reduced in infected and 14C11 treated and in tg2 HRV16
challenged mice (Figure 6C). A single dose of 14C11 was therefore
able to decrease HRV16-induced cellular infiltration in the lung,
induction of cytokines and chemokines, and the induction of
HRV16-specific antibodies over a sustained period of 7 days.
14C11 pre-treatment prevents HRV16-induced
exacerbation of allergic airway inflammation in vivo
Allergic asthma is exacerbated by viral infections, especially by
HRV infections. To model virus-induced exacerbations of allergic
airway inflammation, transgenic positive mice were sensitised and
challenged with OVA, and infected with HRV16. We asked
whether 14C11 could prevent HRV16-induced exacerbation of
Figure 5. 14C11 does not inhibit inflammation induced via mechanisms independent of human ICAM-1.Mice were dosed intravenously
with 14C11 24 hours prior to intranasal dosing with HRV1B, UV-inactivated HRV1B (UV) or HRV16 (n = 4 for tg2 UV, tg2 1B, tg+ 16 iso and tg+ 16
14C11 groups; n = 6 for tg+ UV, tg+ 1B, tg+ 1B iso and tg+ 1B 14C11 groups). (A)Total BAL cells, neutrophils (on day 1) and lymphocytes (on day 4)
were assessed with differentially stained cytospins. Data expressed as mean (6 SEM). Significance was assessed by One-way ANOVA test with
Bonferroni’s Multiple Comparison test as post-test. ***p,0.001 vs UV-RV1B in transgenic negative mice; ###p,0.001 vs UV-RV1B in transgenic
positive mice; 1p,0.05 and 111p,0.001 vs isotype treated HRV16 infected transgenic positive mice. Data are representative of 2 independent
experiments. (B) Groups of 7 mice were dosed intravenously with 14C11 24 hours prior to intranasal dosing with 1 mg LPS/mouse. Total BAL cells,
lymphocytes and neutrophils were assessed with differentially stained cytospins day 1 after infection. Data are expressed as mean (6 SEM).
Significance was assessed by One-way ANOVA test with Bonferroni’s Multiple Comparison test as post-test. *p,0.05, **p,0.01 and ***p,0.001 vs
transgenic positive mice without treatment. Data are representative of 2 independent experiments.
doi:10.1371/journal.ppat.1003520.g005
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allergic airway inflammation. The asthma-like phenotype with
eosinophilic airway inflammation was confirmed in all 3 groups
challenged with OVA on day 6 after infection (Figure 7B). Mice
not challenged with OVA, but HRV16 infected (RV-PBS) showed
increased neutrophil numbers on day 2 compared to UV-HRV16
infected mice (UV-PBS). Compared to mice challenged with UV-
inactivated HRV16 and OVA (UV-OVA), HRV16 and OVA
challenge in isotype pre-treated tg+ mice (RV-OVA iso) signifi-
cantly increased total BAL cell and neutrophil numbers on day 2
after infection, lymphocyte numbers on day 6 and increased
airway hyper-responsiveness as measured by PenH at 24 hrs post-
challenge. 14C11 pre-treated, HRV16 and OVA challenged mice
(RV-OVA 14C11) showed reduced numbers of total BAL cells,
neutrophils and lymphocytes (Figure 7A and B). RV-OVA-14C11
treatment also reduced the exacerbation of airway hyper-
responsiveness to UV-OVA control levels on day 1 after infection
(Figure 7C).
To further investigate the impact of 14C11 pre-treatment on
HRV16-induced allergic airway inflammation we analysed Th2-
type cytokine concentrations as well as the neutrophil and
Figure 6. Time course of topically dosed 14C11 antibody-mediated inhibition of major group HRV16 infection. Mice were dosed
intranasally with 14C11 or isotype control 2 hours prior to intranasal infection with HRV16. (A)Total BAL cells, macrophages, lymphocytes and
neutrophils were assessed with differentially stained cytospins day 2, 4 and 7 after infection. (B) CXCL1, CXCL10 and CXCL11 in the BAL were
determined by MSD or quantitative ELISA. (C) HRV16 specific serum IgG1 and IgG2a on day 7 post-infection. Data are a pool of 2 experiments with
n = 4 mice per group each. Data are expressed as mean (6 SEM). Significance was assessed by Three-way analysis of variance (A and B) or by One-way
ANOVA with Bonferroni’s Multiple Comparison test as post-test (C). **p,0.01 and ***p,0.001 vs HRV16 infected transgenic negative mice; #p,0.05
and ###p,0.001 vs HRV16 infected transgenic positive mice.
doi:10.1371/journal.ppat.1003520.g006
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eosinophil chemokine attractants CXCL1 in BAL and eotaxin-1
levels in lung homogenate at day 2 after infection. Higher levels of
IL-4, IL-5 and IL-6 were found in RV-OVA iso mice compared to
mice receiving RV-OVA 14C11 treatment (Figure 7D). The level
of IL-13 in OVA challenged groups was not increased by virus and
therefore no effect of 14C11 treatment was observed. The
neutrophil attractant CXCL1 was induced in all groups infected
with HRV16 but not modulated by OVA. However, 14C11
administration reduced the level of CXCL1 in RV-OVA
challenged animals. RV-OVA 14C11 treated mice exhibited a
small but significant reduction in eotaxin-1 levels compared to
RV-OVA iso treated controls (Figure 7D). Total IgE levels
measured in serum were not significantly increased by virus
infection and not altered by 14C11 pre-treatment.
Because in asthma exacerbations, increased inflammation and
mucus production have been observed we analysed the impact of
14C11 on mucus production in HRV16-exacerbated allergic
airway inflammation. RV-OVA iso challenged mice showed a
small increase in the production of mucins MUC5AC and
MUC5B compared to mice challenged with UV-OVA challenge.
14C11 pre-treatment of RV-OVA challenged mice significantly
reduced the induction of both MUC5AC and MUC5B mucus
proteins 6 days after infection (Figure 7E). Our data showed that
neutralisation of the HRV16 entry receptor ICAM-1 by 14C11
reduced HRV16-induced allergic airway inflammation in vivo.
These data indicate the possibility to design a domain-specific
anti-ICAM-1 antibody to specifically hinder major group HRV
entry and replication without blocking the crucial LFA-1 function
for unaltered cell recruitment to the site of infection. We have
shown for the first time a major group allergen-induced asthma
exacerbation model and the possible use of a domain-specific anti-
ICAM-1 antibody as possible treatment for rhinoviral triggered
exacerbations of asthma.
Discussion
Human rhinovirus infection is the most common infection
afflicting mankind and is responsible for enormous morbidity and
societal costs as the major cause of the common cold. It also causes
severe morbidity, mortality and health care costs as a key trigger of
acute exacerbations of lung diseases such as asthma, COPD and
cystic fibrosis. In this study, we demonstrate that an anti-ICAM-1
domain-specific antibody can effectively block entry and replica-
tion in an in vivo model of human rhinovirus infection and reduce
rhinovirus-induced exacerbation of allergic airway inflammation,
without preventing ICAM-1 interaction with its cellular ligand
LFA-1, which is required for cell recruitment during respiratory
infections. Thus 14C11 and other antibodies with similar
specificities could be useful agents to help reduce rhinovirus
induced respiratory exacerbations. .
The majority of HRVs use a single cellular receptor, ICAM-1,
for attachment to cells and therefore ICAM-1 is an interesting
target to block virus-receptor binding to prevent rhinovirus
infection. Several alternative approaches have been investigated,
but have not been taken further in clinical trials or had to be
abandoned because of side effects. For example, soluble ICAM-1
(tremacamra, BIRR4) reduced the severity of experimental colds
[26], but was not developed further potentially due to the expense
of manufacturing recombinant proteins as drugs, as well as the
frequency of dosing required. Interferon-alpha used intranasally
was also shown to be effective against HRV infection, but had side
effect including leukopenia and nasal bleeding [27]. The HRC 3C
protease inhibitor (Ruprintrivir) was reported to reduce the
proportion of subjects with positive viral cultures and viral titres
but did not decrease the frequency of colds [28,29]. Pleconaril has
also been shown to be clinically effective in reducing the duration
of colds, but did not get approval due to its side effects profile
[30,31]. Lack of cross-protection between different serotypes of
HRV has also meant that no successful vaccine has been
developed and thus no specific therapy against HRVs exists, even
though there is a very high medical need.
Antibody therapy is an attractive alternative therapeutic
approach, as a single injection can provide protection of long
duration. In this present study we have identified a human ICAM-
1 specific antibody, 14C11, which specifically binds to domain 1 of
human ICAM-1 (Figure 1), the rhinovirus binding domain [32].
14C11 was able to block infection in vitro with HRV16 and
HRV14, members of the HRV A-type and B-type group,
respectively. Moreover, 14C11 was able to block a wide range
of other major group rhinovirus strains, suggesting that blocking of
rhinovirus entry and replication with 14C11 could be seen as
broad spectrum blocking agent for major group rhinoviruses
(Figure 2).
ICAM-1, through its interaction with LFA-1 is also important in
cell trafficking, and ICAM-1/LFA-1 interactions are reported to
involved domains 1 of the ICAM-1 molecule [32], thus antibodies
to ICAM-1 have theoretical potential to inhibit cell trafficking
through blocking ICAM-1/LFA-1 interaction. Binding assays
using the Jurkat human T cell line have shown that 14C11, in
contrast to another anti-ICAM-1 antibody 84H10, did not
interfere with LFA-1 interaction and therefore that this human
ICAM-1 domain 1-specific antibody potentially only hinders HRV
entry and replication (Figure 1).
To test the 14C11 antibody in vivo we infected transgenic mice
over-expressing a chimeric ICAM-1 molecule, consisting of mouse
ICAM-1 in which domains 1 and 2 were replaced with human
ICAM-1 domains 1 and 2 [24], with the major group rhinovirus
HRV16. We observed a cellular infiltration in the lung in HRV16
infected transgenic positive mice, comprising an increase in total
BAL cells, lymphocytes and neutrophils, which was decreased in a
dose dependent manner by topical administration of 14C11 for all
parameters. Chemokines and cytokines in BAL and lung
homogenate were also significantly reduced by 14C11 treatment.
In addition, rhinovirus replication in transgene positive mice was
completely blunted with 14C11 treatment, suggesting that
blocking of all ICAM-1 binding sites in the lung can prevent
HRV entry and replication in vivo. Histological analysis confirmed
that treatment with 14C11 reduced inflammatory cell infiltration
Figure 7. Effect of topically dosed 14C11 antibody on HRV16 induced exacerbation of allergic airway inflammation in vivo. Groups
of 8 transgenic positive mice were OVA sensitised on day213 and re-challenged either with PBS or OVA on day22 and day21. On day 0 mice were
dosed intranasally with 14C11 or isotype control 2 hours prior to intranasal challenge with PBS or OVA and infected HRV16 (RV-PBS and RV-OVA) or
UV-inactivated HRV16 (UV-PBS or UV-OVA). (A) Total BAL cells, neutrophil and macrophage numbers were assessed on day 2 after infection and (B)
lymphocyte and eosinophil numbers on day 6 after infection. (C) Airway hyper-responsiveness was determined on day 1 after infection. The levels of
cytokines and chemokines (D) IL-4, IL-5, IL-13, IL-6 and CXCL1 in BAL and CXCL11 in lung homogenate 2 days after infection. (E) Total IgE in serum and
levels of MUC5AC and MUC5B protein in BAL on day 6 after infection. Significance was assessed by One-way ANOVA test with Bonferroni’s Multiple
Comparison test as post-test. *p,0.05, **p,0.01 and ***p,0.001 vs transgenic positive mice pretreated with isotype control and challenged with
RV-OVA. Data are representative of 3 independent experiments.
doi:10.1371/journal.ppat.1003520.g007
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of the lung and was comparable to the lack of infiltration obtained
by challenge of non-transgenic littermates with HRV16 (Figure 3).
Genome sequence places HRV16 in group A which also
contains the majority of ICAM-utilising major group viruses (63
out of a currently identified 88 serotypes). HRV14 is amongst a
significant minority of genetically distinct major group viruses (25
serotypes) that belong to group B viruses [17]. We could
additionally show that infection with HRV14 could be prevented
by 14C11 in vivo. Cellular infiltration in the lung, as well as
cytokine and chemokine levels in BAL and lung homogenate were
all reduced by topical administration of 14C11 (Figure S2). Thus
ICAM-1 blockade has shown efficacy in vivo against representative
serotypes of both species of major group rhinoviruses. Of the 99
serotyped rhinovirus strains, major group viruses which use
ICAM-1 and which can potentially be specifically blocked by
14C11 constitute 88 serotypes, while minor group viruses, which
do not use ICAM-1 and which therefore would not be treated with
14C11, constitute only 11 serotypes, thus 14C11 has potential to
treat 89% of serotyped rhinovirus strains. A third group of
rhinoviruses named group C viruses has been recently identified
based on RNA genome sequence analysis [33]. The size of this
group of rhinoviruses is estimated on sequence analysis to be
around 60 virus strains. Viruses in this group have not been
serotyped as they have not yet been successfully cultured in a cell
line [16], however based on sequence analysis, it is assumed that
this group of viruses will not use ICAM-1 as their cellular receptor
[16]. If this is confirmed by experimental data antibodies targeting
the same epitope to 14C11 and thus only inhibiting major group
virus entry would be anticipated to block,55% of rhinovirus
strains known to date.
Therapeutic use of antibodies in man normally involves
systemic rather than inhaled dosing, for this reason we wished to
determine if systemic dosing with 14C11 would successfully inhibit
rhinovirus induced airway inflammation. Systemic dosing of
14C11 did prevent HRV16 induced inflammation and proin-
flammatory cytokine release, thus showing pharmacological
activity of 14C11 via the intravenous route and suggesting the
suitability of parenteral dosing for route of administration for an
anti-ICAM1 based therapy (Figure 4 and Figure S3).
To investigate the human ICAM-1-specificity of the action of
14C11 in vivo and to exclude possible interactions of the Fc part of
the 14C11 antibodies we tested for possible inhibition by 14C11 in
minor group HRV infection, which does not use human ICAM-1 as
virus entry receptor and in an LPS challenge model where induction
of airway inflammation is independent of human ICAM-1 (Figure 5
and Figure S3). In both models of airway inflammation, we found
that 14C11, which does not bind mouse ICAM-1 in vitro (Figure 1),
also had no effect on human ICAM-1 independent airway
inflammation in vivo. These data confirmed that the inhibition of
HRV infection and induction of airway inflammation in vivo was
specifically a consequence of blockage of rhinovirus entry and
replication, and not due to non-specific effects.
We next investigated whether a single administration of 14C11
prior to HRV infection was effective in significantly inhibiting later
outcomes of HRV infection. Complete inhibition of HRV induced
total cell counts, macrophages, lymphocytes and neutrophils as
well as virus-specific antibody induction were achieved up to 7
days after administration of 14C11 (Figure 6), thus strengthening
our hypothesis that domain specific blocking of HRV entry and
replication could be a potential anti-viral approach in man. These
data also confirmed that 14C11 treatment completely arrested,
rather than simply retarded HRV infection in vivo.
Having shown that this antibody could inhibit rhinovirus
infection and induction of inflammation in vivo, we next wished to
test the antibody in a model of disease where the costs in man
would justify the development of a relatively expensive treatment
such as a therapeutic antibody. Rhinovirus infections are
responsible for the majority of acute exacerbations of asthma
and exacerbations are responsible for around 50% of asthma
related health care costs [34]. We therefore tested the antibody in
a mouse model of rhinovirus exacerbation of allergic airway
inflammation [24]. We show that 14C11 was effective in
suppressing each of the outcomes that were exacerbated by
rhinovirus infection superimposed on a model of ovalbumin
induced allergic airway inflammation, including HRV-induced
exacerbation of total cellular, neutrophilic and lymphocytic airway
inflammation, as well as Th2 (IL-4 and IL-5) and pro-inflamma-
tory (IL-6) cytokine and neutrophil (CXCL1) and eosinophil
(eotaxin) recruiting chemokine release. Additionally, 14C11
treatment significantly suppressed HRV exacerbation of the two
major respiratory mucins MUC5AC and MUC5B, and impor-
tantly, airway hyper-responsiveness.
In conclusion we have shown that the human ICAM-1 domain
1-specific antibody 14C11 inhibits major group HRV infection in
vitro and in vivo, as well as inhibiting major group HRV-induced
exacerbation of allergic airway inflammation in vivo. This antibody
however did not interfere with human ICAM-1 binding to its
ligand on human T cells and further it had no non-specific effects
on cell recruitment in models of airway inflammation induced by
mechanisms independent of human ICAM-1. This antibody and
others with similar properties would therefore be good candidates
for development of novel treatments for diseases induced by major
group rhinoviruses – principally acute exacerbations of airway
diseases such as asthma, COPD and cystic fibrosis.
Materials and Methods
Ethics statement
All animal work was completed in accordance with UK Home
Office guidelines following approval via the ethical approval
process (UK project licence PPL 70/7234 valid 03/03/2011 to
03/03/2016).
ICAM specificity ELISA
ICAM-1 antigens were generated using mammalian expression
systems. Human ICAM-1 domain 1/mouse ICAM-1 domains 2–5
chimera, and mouse ICAM-1 domains 1–5 were generated in-
house. Human ICAM-1 domains 1–5 was obtained commercially
(R&D Systems 720-IC). All ICAM-1 antigens were biotinylated
via free amines using EZ link Sulfo-NHS-LC-Biotin (Thermo
Scientific). Biotinylated bovine insulin (Sigma I2258) was used as
control for non-specific binding. Streptavidin plates (Thermo
Scientific) were coated with the biotinylated antigens at 1 mg/ml in
PBS and incubated overnight at 4uC. Plates were washed, blocked
(PBS+0.1% BSA) for 1 hour and serial dilutions of anti-ICAM-1
antibody 14C11 (MAB720, R&D Systems) were added in blocking
buffer for 1 hour as indicated in the figures. ELISA to test 14C11
binding specificity used 14C11 and control antibodies from R&D
Systems: anti-mouse ICAM-1 (MAB796) anti-human ICAM-2
(MAB244), anti-human ICAM-3 (MAB813), anti-human ICAM-5
(MAB1173) and anti-human VCAM-1 (MAB809). Plates were
washed and developed with anti-human IgG light chain HRP
antibody (Sigma), TMB and H2SO4. Plates were read on an
EnVisionTM plate reader at 450 nm.
PMA Jurkat cell adhesion assay
Human ICAM-1-Fc (R&D Systems) was coated onto 96-well
black walled plates at 10 mg/ml in PBS overnight at 4uC. Plates
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were then washed and blocked with assay buffer (phenol-red free
HBSS plus 1% BSA) for 1 h. Antibodies (14C11, 84H10 (Serotec)
and muIgG1 isotype control were serially diluted in assay buffer
(46 final concentration) and 50 ml/well transferred to ICAM-1-Fc
coated plates. After a 15 min incubation period at room
temperature, a further 50 ml/well of PMA (50 ng/ml) in assay
buffer was then added. During this time, Jurkat E6.1 cells were
harvested and labelled with Calcein-AM dye (5 mM in phenol-red
free RPMI 1640) for 30 minutes at 37uC. Following washing, 105
Jurkat E6.1 cells were added to each well in 100 ml assay buffer.
Plates were then incubated for a further 3 h at 37uC/5% CO2.
Adhesion of the cells to the plate was assessed following aspiration
of the plate and washing with 250 ml wash buffer (150 mM
HEPES, 0.1% glucose, 2 mM MgCl2 pH 7.2). A final 250 ml of
wash buffer was added and plates were read for fluorescein
detection. Data are expressed without PMA (0% signal) and with
PMA and no antibody (100% signal).
Cytopathic effect assay
HeLa Ohio cells (ECACC) were seeded at 36104/well into 96
well plates in MEM (minimal essential medium) supplemented
with 16 non-essential amino acids, penicillin (100 U/ml),
streptomycin (100 mg/ml) (each from Invitrogen, Paisley, UK)
and heat inactivated bovine calf serum (10%), (SAFC Biosciences,
Andover, UK). After an overnight incubation (37uC/5% CO2) the
media was removed and replaced with serially diluted anti-ICAM-
1 antibody 14C11, mIgG1 isotype control (R&D Systems,
Abingdon) or medium alone for untreated controls and incubated
at 37uC for 30 minutes. Following this, 30 ml of HRV16 or
HRV14 culture supernatant (multiplicity of infection predeter-
mined to induce 80–90% CPE) was then added to the wells (or
medium alone for un-infected controls) and virus attachment was
allowed to proceed for 2 hours at 33uC/5% CO2. Assay
supernatants were then removed and 100 ml of fresh medium
was added to each well and incubated for a further 23 hours at
33uC/5% CO2. Remaining viable cells were fixed in 4%
formaldehyde (Sigma-Aldrich, Poole, UK), stained with 0.5% w/
v crystal violet (Sigma-Aldrich, Poole, UK) for 5 minutes, washed
3 times in water to remove excess stain and allowed to dry. The
extent of CPE was quantified by measuring absorbance at 600 nm
and calculated according to the equation % CPE=1006[(test
sample2virus only)/(uninfected control2virus only)].
Mice
Human-mouse ICAM-1 transgenic mice were generated as
described previously [24]. Human-mouse ICAM-1 transgenics
were bred in-house and transmission of the chimeric transgene was
confirmed by PCR. Mice bearing the human-mouse ICAM-1
transgene are referred in the paper as tg+ and mice not expressing
the transgene are referred as tg2.
Viruses
HRV were grown in HeLa Ohio cells. Infected cells were
harvested after 24 hours and HRV was concentrated and purified
as described previously [24]. Viral titers were assessed by TCID50
assay (50% tissue culture infectivity dose). The identity of HRV1B,
HRV14 and HRV16 working stocks were confirmed by neutral-
isation with serotype specific antibodies (ATCC). The HRV
infection and HRV-induced asthma exacerbation models have
been described previously [24]. For infection studies mice were
infected with 56106 TCID50/ml of the indicated HRV. For the
mouse asthma exacerbation model mice were infected with
2.56106 TCID50/ml. To demonstrate HRV replication-specific
responses HRV1B and HRV16 were UV-irradiated using a UV
Stratalinker 2400 (Stratagene).
Human rhinovirus infection model
Mouse anti-human ICAM-1 antibody 14C11 (MAB720, R&D
Systems) and mouse IgG1 isotype control (MAB002, R&D
Systems) was used as a 0.2 mm filtered solution dissolved in PBS.
5 to 7 week old transgenic positive (tg+) or transgenic negative
(tg2) females were lightly anaesthetised and dosed intranasally
with mouse anti-human ICAM-1 antibody 14C11 or isotype
control 2 hours prior to challenge with HRV16 or HRV14. For
intravenous treatment, 14C11 or isotype control was administered
in the tail vein 24 hours before infection with HRV16, HRV1B or
UV-inactivated HRV1B (UV-HRV1B). Bronchoalveolar lavage
(BAL) was performed using 1.5 ml BAL buffer (EBSS, 55 mM
EDTA, 12 mM lidocaine) 1, 2, 4 or 7 days after infection, as
indicated. BAL supernatant was aliquoted and stored for cytokine
and chemokine analysis. BAL cells were counted and processed
onto slides by cytospin, differentially stained (Quick Diff, Reagena,
Finland) and counted blind to experimental conditions. 300 cells
were counted per slide. The small upper lung lobe was stored in
RNAlater (Qiagen) for mRNA analysis. The remaining lung tissue
was homogenised in 2 ml of PBS, clarified by centrifugation and
stored for cytokine and chemokine analysis.
HRV-induced asthma exacerbation model
5 to 7 week old transgenic positive females were injected
intraperitoneally (i.p.) with 50 mg OVA (Albumin from chicken
egg, Calbiochem) and 2 mg aluminium hydroxide (Sigma) in a
volume of 200 ml on day 213. Lightly anesthetised mice were
challenged with 40 mg OVA/mouse on day 22 and day 21 to
induce allergic airway inflammation. On day 0 anesthetised mice
were challenged either with 20 mg OVA or PBS and infected with
HRV16 or dosed with UV-inactivated HRV16 (RV-OVA, UV-
OVA or RV-PBS, UV-PBS). Airway hyper-reactivity (AHR) was
assessed by whole body plethysmography on day 1 after infection
in response to increasing doses of nebulised methacholine (MCh).
BAL supernatant and cells were collected at day 2 or day 6 after
infection and processed as described above.
Quantification of cytokines and chemokines, IgE, mucus
and tissue infiltration
Cytokines and chemokines in BAL or lung homogenate were
measured by ELISA using commercial kits from R&D Systems or
Meso Scale Discovery. IL-4, IL-5 and IL-13 were measured with
R&D Quantikine ELISA kits; eotaxin, IP-10, ITAC and IFNl2/3
were measured with R&D Duosets; IL-1b, IL-6 and CXCL1 were
measured with MSD multi-array according to the manufacturer’s
recommendations. Total IgE was measured in serum with BD
OptEIA (BD Bioscience) according to the manufacturer’s instruc-
tions. Mucins MUC5AC and MUC5B were determined by
semiquantiative ELISA: BAL fluid was diluted in PBS and dried
over night in Maxisorp plates (Nunc). MUC5AC was detected using
a biotinylated anti-MUC5AC antibody (Neomarkers) and detected
with streptavidin-HRP (Invitrogen) and TMB (Sigma). MUC5B
was detected using an anti-MUC5B antibody (Santa Cruz
Biotechnology) and developed using a biotinylated anti-mouse
IgG antibody (Sigma), streptavin-HRP and TMB. Lung tissues were
freshly fixed in 10% buffered formaldehyde, embedded in paraffin
wax, sectioned 5 mm thick and stained with haematoxylin-eosin
(H&E). The morphology of H&E stained sections were visualized
and images acquired using an Axioskop 40 light microscope with
AxiCamMRc 5 digit camera (Zeiss, West Germany).
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HRV-specific antibody enzyme-linked immunosorbent
assay
Nunc Maxisorp Immuno plates were coated with purified HRV
stock in PBS overnight. After blocking, diluted serum samples
were incubated for 1 hour, followed by detection with biotinylated
rat-anti-mouse IgG1 or IgG2a antibodies. The assay was
developed with streptavidin-HRP and TMB as substrate.
LPS challenge model
Transgenic positive mice were dosed intravenously with 14C11
24 hours prior to intranasal challenge with 1 mg LPS/mouse.
Lipopolysaccharide (LPS) from E. coli 055:B5 was purchased from
Sigma. BAL was collected and processed as described above.
Quantitative real-time PCR
The left upper lung lobe was stored in RNAlater (Qiagen) until
RNA was purified using the RNeasy Mini kit (Qiagen) and the
RNase-free DNase set (Qiagen). Isolated RNA was reverse-
transcribed using random hexamer primers (OmniscriptRT kit,
Qiagen). Real-time PCR was performed with the Quantitect
Probe PCR master mix (Qiagen). Primers and probes for 18S
rRNA (forward: 59cgc cgc tag aggtgaaattct; revers: 59cat
tcttggcaaatgctttcg and probe: FAM59acc ggcgcaagacggaccaga)
and HRV specific primers (forward: 59 gtgaagagccscrtgtgc t;
reverse: gctscagggttaaggttagcc and probe FAM59tga gtcctccgg ccc
ctgaat g) were used for quantification of HRV16 vRNA.
Statistical analysis
All data were distributed normally and data are expressed as
means 6 SEM. Data were analysed with Prism3 (Graph Pad) or
SAS Version 8.
Supporting Information
Figure S1 The antibody 14C11 is specific for domain 1
of human ICAM1 and does not cross-react with other
ICAM family members. To determine antibody specificity
14C11 was tested for binding to a panel of ICAM family members.
Using an ELISA 14C11 was incubated with human (Hu) ICAM1,
Mouse ICAM1, Hu ICAM-2, -3, -5 and Hu VCAM1. In addition
a chimeric protein consisting of human ICAM1 domain 1 (Hu D1)
and mouse domains 2 to 5 (Mu D2-5) was evaluated. Specific anti-
ICAM-2, -3, -5 and VCAM1 antibodies were used as positive
controls. Recombinant insulin was also used as a negative control
to determine non-specific binding.
(TIF)
Figure S2 Topically dosed 14C11 antibody inhibits
HRV14 induced inflammation. Groups of 6 mice were dosed
intranasally with 14C11 2 hours prior to intranasal infection with
HRV14. (A) Total BAL cells, macrophages, lymphocytes and
neutrophils were assessed with differentially stained cytospins day 2
after infection. (B) The levels of proinflammatory cytokines and
chemokines IL-1b, IL-6, CXCL1, IFNl3, CXCL11 and CXCL10
in BALwere determined byMSD or quantitative ELISA 2 days after
infection. (C) The levels of proinflammatory cytokines and
chemokines IL-1b, IL-6 and CXCL1 in lung homogenate were
assessed with MSD 2 days after infection. Data are expressed as
mean (6 SEM). Significance was assessed by One-way ANOVA test
with Bonferroni’s Multiple Comparison test as post-test. *p,0.05,
**p,0.01 and ***p,0.001 vs HRV14 infected transgenic negative
mice; ##p,0.01 and ###p,0.001 vs HRV14 infected transgenic
positive mice. Data are representative of 2 independent experiments.
(TIF)
Figure S3 Systemically dosed 14C11 antibody inhibits
HRV16 induced inflammation. Mice were dosed intrave-
nously with 14C11 24 hours prior to intranasal infection with
HRV16 (n= 9 for tg2 group; n = 6 for tg+ groups). (A) The levels
of proinflammatory cytokines IL-1b, IL-6, IFNl2/3 were
determined in BAL by MSD or quantitative ELISA. (B) The
levels of proinflammatory cytokines and chemokines IL-1b, IL-6
and CXCL1 in lung homogenate were assessed with MSD. Data
are expressed as mean (6 SEM). Significance was assessed by
One-way ANOVA test with Bonferroni’s Multiple Comparison
test as post-test. **p,0.01 and ***p,0.001 vs HRV16 infected
transgenic negative mice; #p,0.05, ##p,0.01 and ###p,0.001
vs HRV16 infected transgenic positive mice; Data are represen-
tative of 3 independent experiments.
(TIF)
Figure S4 Systemically dosed 14C11 antibody specifi-
cally inhibits major group HRV induced inflammation.
Mice were dosed intravenously with 14C11 24 hours prior to
intranasal infection with minor group HRV1B, UV-inactivated
HRV1B (UV) or major group HRV16 (n = 4 for tg2 UV, tg2
1B, tg+ 16 iso and tg+ 16 14C11 groups; n = 6 for tg+ UV, tg+
1B, tg+ 1B iso and tg+ 1B 14C11 groups). (A) Total BAL cells,
macrophages, neutrophils (day 1 p.i.) and lymphocytes (day 4
p.i.) were assessed with differentially stained cytospins. (B) The
levels of proinflammatory cytokines IL-1b, IL-6, CXCL1 and
IFNl3 in BAL were determined by MSD or quantitative ELISA
day 1 after infection. (C) The levels of proinflammatory cytokines
and chemokines IL-1b, IL-6 and CXCL1 in lung homogenate
were assessed with MSD day 1 after infection. Data are
expressed as mean (6 SEM). Significance was assessed by
One-way ANOVA test with Bonferroni’s Multiple Comparison
test as post-test. *p,0.05, **p,0.01 and ***p,0.001 vs UV-
RV1B in transgenic negative mice; #p,0.05, ##p,0.01 and
###p,0.001 vs UV-RV1B in transgenic positive mice; 1p,0.05
and 111p,0.001 vs isotype treated HRV16 infected transgenic
positive mice. Data are representative of 2 independent
experiments. Groups of 7 mice were dosed intravenously with
14C11 24 hours prior to intranasal infection with 1 mg LPS/
mouse. (D) The levels of proinflammatory cytokines IL-1b, IL-6
and IFNl3 in BAL were determined by MSD or quantitative
ELISA day 1 after infection. (E) The levels of proinflammatory
cytokines and chemokines IL-1b, IL-6 and CXCL1 in lung
homogenate were assessed with MSD day 1 after infection. Data
are expressed as mean (6 SEM). Significance was assessed by
One-way ANOVA test with Bonferroni’s Multiple Comparison
test as post-test. *p,0.05, **p,0.01 and ***p,0.001 vs
transgenic positive mice without treatment. Data are represen-
tative of 2 independent experiments.
(TIF)
Figure S5 Time course of topically dosed 14C11 anti-
body in major group HRV16 infection model. Mice were
dosed intranasally with 14C11 or isotype control 2 hours prior to
intranasal infection with HRV16. (A) The levels of proinflamma-
tory cytokines IL-1b, IL-6, IFNl2/3 were determined in BAL by
MSD or quantitative ELISA. (B) The levels of proinflammatory
cytokines and chemokines IL-1b, IL-6 and CXCL1 in lung
homogenate were assessed with MSD. Data are expressed as mean
(6 SEM). Significance was assessed by Three-way analysis of
variance. **p,0.01 and ***p,0.001 vs HRV16 infected trans-
genic negative mice; #p,0.05, ##p,0.01 and ###p,0.001 vs
HRV16 infected transgenic positive mice. Data are a pool of 2
experiments with n= 4 mice per group each.
(TIF)
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